Liquid Biopsies Programme

Lyon, France

22 - 24 September 2026

Scientific Programme

Tuesday 22nd September 2026

Listed times are in Central European Summer Time (CEST)

11:30 REGISTRATION

Light refreshments will be served at 12:00

13:00 CONFERENCE WELCOME

SESSION 1: UNVEILING THE BIOLOGY BENEATH THE BIOMARKERS: MECHANISMS DRIVING LIQUID BIOPSY SIGNALS

Chair: Ellen Heitzer

13:10 OPENING KEYNOTE LECTURE

Efrat Shema

Weizmann Institute of Science, Israel

'Single-molecule epigenetic analysis of plasma-circulating nucleosomes for cancer diagnosis'

Q&A 13:40-13:55

13:55 **Amin El-Heliebi**

Med Uni Graz, Austria

'Integrating liquid biopsy and spatial transcriptomics for understanding ctDNA release'

Q&A 14:15-14:25

14:25 **Sangmi Lee**

Harvard Medical School, USA

Proferred Paper 1: 'Mechanistic interpretation of cfDNA fragmentation topography through joint deconvolution of fragmentation processes and tissue composition with cfVista'

Q&A 14:35-14:40

14:40 EXHIBITOR INTRODUCTIONS

15:00 COFFEE BREAK, EXHIBITION AND SOLO TRAVELLERS' MEET-UP

15:30 **Remond Fijneman**

NKI, Netherlands

'Impact of tumor location and host factors on ctDNA shedding'

Q&A 15:50-16:00

16:00 **Mischa Steketee**

Amsterdam UMC, Netherlands

Proferred Paper 2: 'Tumor-Informed Deconvolution of Circulating Extracellular Vesicle RNA in Large B Cell Lymphoma Patients Reveals On-treatment Tumor-Microenvironment Evolution'

Q&A 16:10-16:15

16:15 Marie Bernkopf
St. Anna Children's Cancer Research Institute, Austria
Proffered Paper 3: 'Sensitive detection of relapse and immunotherapy targets by blood and bone marrow multi-modal liquid biopsy analysis in high-risk neuroblastoma'

Q&A: 16:25-16:30

16:30 POSTER SPOTLIGHTS

Wenhan Chen (Australia) 'Improving paediatric cancer care by leveraging a new ultra-sensitive ctDNA assay'

Kate Glennon (Germany) 'Nucleosomal profiling infers ER status in longitudinal breast cancer liquid biopsies'

Parisa Mapar (Netherlands) 'Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Large B-Cell Lymphoma'

16:40 INDUSTRY SYMPOSIUM - BIOMODAL
Tom Charlesworth
Director of Market Strategy & Corporate Development, biomodal
'Single stranded 6-base workflow optimises discovery of integrated genetic, epigenetic and fragmentomic biomarkers for sensitive ctDNA detection'

17:10 PANEL DISCUSSION
'Where is liquid biopsy heading in the next 5–10 years? Clinical implementation, standardization and regulatory challenges'

17:50 WELCOME RECEPTION

18:20 POSTER DISCUSSION SESSION 1
Led by members of the Scientific Programme Committee

Wednesday 23rd September 2026

Listed times are in Central European Summer Time (CEST)

08:15 EARLY POSTER VIEWING

Chair: Claus Lindbjerg Andersen

08:45 INDUSTRY SPOTLIGHT - ULTIMA GENOMICS
Alex Watkins
Staff Field Applications Scientist
'Using Ultima Genomics technology to detect minimal residual disease'

SESSION 2: TRACKING THE UNSEEN: LIQUID BIOPSIES IN ADVANCED AND METASTATIC CANCER

09:00 **Karen-Lise Garm Spindler**
Aarhus University, Denmark
'Using ctDNA for response evaluation in solid tumors – a paradigm shift in medical oncology?'

Q&A 9:20-9:30

09:30 **Peter Ulz**
Medical University Graz, Austria
Proferred Paper 4: 'Landscape of somatic copy-number alterations in advanced breast, prostate and colorectal cancers by longitudinal shallow whole-genome sequencing of cell-free DNA'

Q&A 09:40-09:45

09:45 **Ellen Heitzer**
Meduni Graz, Austria
'Signal vs Noise: The Reality of ctDNA in Advanced Disease'

Q&A 10:05-10:15

10:15 **Irene Casanova**
VHIO, Spain
'EV-enhanced liquid biopsy for tumor dynamics in metastatic Prostate Cancer'

Q&A 10:35-10:45

10:45 COFFEE BREAK AND EXHIBITION

11:15 **François Clément Bidard**
Institut Curie & UVSQ/Université Paris-Saclay, France
'Intercepting late resistance to therapy with ctDNA: ESR1 mutations and beyond'

Q&A 11:35-11:45

11:45 **Galatea Kallergi**
University of Patras, Greece
Proferred Paper 5: 'Unraveling the Phenotypic Heterogeneity of Tumor-Derived Cells in the Bloodstream of Pancreatic Cancer Patients'

Q&A 11:55-12:00

12:00 POSTER SPOTLIGHTS

Kyle Smith (USA) 'M-PACT-GLOBAL: a pediatric pan-cancer classifier for cell-free DNA methylomes'

Roma Sunder (Spain) 'Longitudinal multimodal liquid biopsy profiling to characterize treatment response dynamics in metastatic Prostate Cancer: Interim results from the MARION clinical study'

12:10 INDUSTRY SYMPOSIUM - BECTON DICKINSON
Markus Wolf
PreAnalytix, Senior Scientist R&D
'From Blood Draw to Insight: Key Considerations in Preparing Diagnostic Liquid Biopsy Specimens for ccfDNA Analysis'

12:40 LUNCH

13:30 POSTER DISCUSSION SESSION 2
Led by members of the Scientific Programme Committee

SESSION 3: FRONTIERS IN LIQUID BIOPSY TECHNOLOGY: FROM FRAGMENTOMICS TO FUNCTIONAL READOUTS
Chair: Nikolas Stoecklein

15:00 **Mette Agerbæk**
University of Copenhagen, Denmark
'Oncofetal Chondroitin Sulfate: A circulating biomarker on tumour-derived CTCs, EVs, and soluble proteoglycans'

Q&A 15:20-15:30

15:30 **Anton Fornies Marine**
IDIBAPS, Spain
Proferred Paper 6: 'Cell type signatures derived from cfDNA fragmentation

profiles in patients with melanoma or benign melanocytic lesions'

Q&A 15:40-15:45

15:45 **Nikolas H. Stoecklein**
University of Dusseldorf, Germany
'From Milliliters to Liters: Diagnostic Leukapheresis Enables High-Volume Liquid Biopsy for Rare CTC Detection'

Q&A 16:05-16:15

16:15 COFFEE BREAK AND EXHIBITION

16:45 **An Hendrix**
Ghent University, Belgium
'Extracellular vesicle-based biomarkers: from technology towards biomedical application'

Q&A 17:05-17:15

17:15 **Anders Jacobsen Skanderup**
Genome Institute of Singapore, Singapore
'Toward Scalable Tumor-Naïve ctDNA Quantification'

Q&A 17:35-17:45

17:45 PANEL DISCUSSION
'Publication strategies and the responsible use of AI in scientific writing'
Scheduled to end at 18:30

19:30 CONFERENCE DINNER (OPTIONAL TICKETED EVENT)

Thursday 24th September 2026

Listed times are in Central European Summer Time (CEST)

08:15 EARLY POSTER VIEWING

Chair: An Hendrix

08:45 INDUSTRY SPOTLIGHT - PARTICLE METRIX
Bertrand Damart
'ZetaView Evolution : a new edge for nanoparticle characterization'

SESSION 4: LIQUID INSIGHTS AT THE EARLIEST STAGE: TRANSFORMING LOCALISED CANCER DETECTION AND INTERVENTION

09:00 KEYNOTE LECTURE
Maximilian Diehn
Stanford University, USA
'Analysis of cell-free RNA for cancer detection and characterization'

Q&A 09:30-09:45

09:45 **Claus Lindbjerg Andersen**
Aarhus University, Denmark
'From Resection to Recurrence Prediction: The Role of Liquid Biopsy in CRC Management'

Q&A 10:05-10:15

10:15 **Christopher Sng**
Institute of Cancer Research, UK

Proferred Paper 7: 'Augmenting circulating tumour DNA (ctDNA) recurrence prediction in resected colorectal cancer (CRC) through primary tumour genome sequencing'

Q&A 10:25-10:30

10:30 COFFEE BREAK AND EXHIBITION

11:00 **Nickolas Papadopoulos**
John Hopkins Medicine, USA
'Quantification of disease burden in acute myeloid leukemia patients'

Q&A 11:20-11:30

11:30 **Angela DeMichele**
Penn Medicine, USA
'ctDNA in the neoadjuvant and adjuvant management of breast cancer: the quest for clinical utility'

Q&A 11:50-12:00

12:00 SUMMARY AND CLOSE